UBS AM’s Kyverna Therapeutics KYTX Stock Holding History
Bought
Maintained
Sold
Other funds holding KYTX
ACM
UBS AM's KYTX Position: Q3 2026 in Review
UBS AM opened a new position in Kyverna Therapeutics (KYTX) in Q3 2026: 625 shares worth $4.25K. The stake represents ﹤0.01% of the portfolio and ranks #3936 among its holdings. This is a return to the name: UBS AM previously reported a position in KYTX as recently as Q3 2024.
UBS AM first reported a position in KYTX in Q1 2024 and has held it in 4 quarters since. The position peaked at $2.63M in Q1 2024. 106 funds tracked by Wall St. Rank hold KYTX as of Q3 2026.
- UBS AM held 625 shares of Kyverna Therapeutics worth $4.25K as of Q3 2026.
- Kyverna Therapeutics was a new UBS AM position in Q3 2026.
- Kyverna Therapeutics made up ﹤0.01% of UBS AM's portfolio in Q3 2026, its #3936 holding.
- UBS AM first reported a position in Kyverna Therapeutics in Q1 2024 and has held it in 4 quarters since.
- UBS AM's Kyverna Therapeutics position peaked at $2.63M in Q1 2024.
- 106 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q3 2026.
Based on UBS AM's 13F filing for Q3 2026, filed 16 Nov 2026.